Pembrolizumab
Merck
['nsclc', 'sclc', 'lcsm,(-blcsm)', 'pearls', 'pearl', 'keynote,91', 'pembro']
pd-l1 expression and outcomes of
pembrolizumab and placebo in
completely resected stage ib-iiia
nsclc: subgroup analysis of pearls/
keynote-091 control arm overperforming in pd-l1&gt;50% w/o dfs differences compared to pembrolizumab arm. #esmo22 #lcsm 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm